Paediatric venous thromboembolism (VTE) is a rare disorder but a rising incidence has been observed in recent years, due to improved VTE diagnosis and increased use of central venous catheters in the treatment of severe diseases. Risk assessment strategies are well established for adult patients, however, similar guidelines for paediatric patients are largely lacking. Several risk prediction tools have been reported in recent literature, which make use of established risk factors to assess VTE risk in paediatric subgroups, such as hospitalised children, cancer-diagnosed children and paediatric trauma patients. Although these models suffer several limitations regarding their study size and heterogeneous selection of predictor variables, they offer potential for improving the thromboprophylaxis management in these children. Here, we give an overview on recently reported risk prediction models for paediatric VTE.
Epidemiology
Venous thromboembolism (VTE) in children is a rare disease with an annual incidence of 0Á07-0Á14 per 10 000 children or 5Á3 per 10 000 hospital admissions of children as estimated in the 1990s (Andrew et al, 1994; van Ommen et al, 2001) . This is substantially lower than the annual incidence of 0Á1% observed in adults (Silverstein et al, 1998; Heit, 2015) . Within the prepubescent childhood population, neonates exhibit the greatest risk for VTE, with 0Á51 incidents per 10 000 live births per year in Caucasian children and 24 per 10 000 admissions to neonatal intensive care units (ICU) (Schmidt & Andrew, 1995; Nowak-G€ ottl et al, 1997) . The incidence of VTE decreases after the first year and increases again during puberty and adolescence of paediatric patients.
There is a dramatic increase in the paediatric VTE incidence rate rising up to 58 cases per 10 000 hospital admissions in the United States in 2007 (Raffini et al, 2009 ). This increase is possibly due to thrombosis as a consequence of successful medical or surgical intervention for childhood disorders, such as prematurity, malignancy and congenital heart disease, as well as the increased use of central venous catheters (CVC) and progress in VTE diagnosis (Biss, 2016; Kenet et al, 2017; van Ommen & Nowak-G€ ottl, 2017) . The consequences of VTE for paediatric patients are significant, including lack of thrombus resolution in 50% of cases, postthrombotic syndrome in about 30% of cases, chronic pulmonary insufficiency, pulmonary hypertension and mortality rate of 2%, rising to 9% among paediatric pulmonary embolism cases (Branchford et al, 2012; Meier et al, 2015; Kenet et al, 2017) .
Risk assessment
There is consensus that VTE risk assessment markedly reduces the rate of VTE in hospitalised adults (Biss, 2016) . Thus, VTE risk assessment in adults has become standard of care, e.g. as proposed in the clinical guideline CG92 from the National Institute for Health and Care Excellence on 'Venous thromboembolism: reducing the risk for patients in hospital' (National Institute of Health and Care Excellence, 2010) .
For children, reliable and comprehensive recommendations for VTE risk assessment and prophylaxis are largely lacking. Current management guidelines of VTE in childhood, as given in the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, provide advice on the choice of anticoagulant, intensity and duration of therapy as well as nature and frequency of monitoring (Monagle et al, 2012 ). An excerpt of these guidelines related to thrombosis prophylaxis is given in Table I . Chalmers et al (2011) recommend pharmacological thromboprophylaxis with low-molecular-weight heparin for children, particularly adolescents, with multiple risk factors for VTE. However, many of these recommendations are based on limited evidence or have been extrapolated from adult data (Chalmers et al, 2011; Monagle et al, 2012; Biss, 2016) . The safety and efficacy of chemical thromboprophylaxis in children remain controversial due to the lower incidence of paediatric VTE and differences in the coagulation system in children.
Children at high risk may benefit from risk prediction, allowing for an adjusted management of deep venous thrombosis (DVT) symptoms, monitoring and prophylactic treatment. The incidence and recurrence risk is increased for children with prothrombotic risk factors, especially if combinations of multiple risk factors apply (Andrew et al, 1994; van Ommen & Nowak-G€ ottl, 2017) . On the other hand, children with low DVT risk may be spared needless anticoagulant treatment, rather than putting them at risk for bleeding while offering little benefit in thrombosis prevention.
Several approaches for risk assessment in paediatric patients or subgroups thereof have recently been described in the literature. Most of them make use of multivariate logistic regression models to stratify the patients in different risk groups and report the model's receiver operating characteristic (ROC) curve and its area under the ROC curve (AUC) statistic to assess the performance of the model in an independent validation dataset. The ROC curve depicts the specificity of the model dependent on its sensitivity. The AUC statistic ranges from 0Á5 to 1. Although no strict thresholds are defined, an AUC ≥ 0Á9 is considered as excellent, ≥0Á8 as good, ≥0Á7 as fair and values below 0Á7 as poor (Carter et al, 2016) . For diagnostic tests an AUC ≥ 0Á9 is desirable. A value of 0Á5 indicates no benefit of the model compared to chance.
Here, we provide an overview on recent efforts for VTE risk prediction modelling in children, which intend to improve management of thromboprophylaxis in paediatric patients at high risk of VTE.
Properties of the paediatric coagulation system
The coagulation system of neonates and children differs from that of adults, especially in the early months of life. The complex system of procoagulant and anticoagulant factors evolves in childhood during the process of developmental haemostasis (Andrew et al, 1992) . Most blood clotting proteins differ in concentration compared to adults. Coagulation factor levels are reduced in neonates to approximately 50% of adult values with preterm new-borns having lower levels than full-term new-borns (Andrew et al, 1987 (Andrew et al, , 1988 Toulon, 2016) . Exceptions from this rule include factor V, factor VIII, factor XIII and von Willebrand factor (VWF). While plasma levels for factor V and factor XIII have been reported close to normal, the levels of factor VIII and VWF are even elevated to about 100-150% throughout the neonatal period (Andrew et al, 1987; Kuhle et al, 2003; Toulon, 2016) . The decreased levels of coagulation factors lead to a disproportionally prolonged activated partial thromboplastin time (aPTT), but to only slight prolongation of prothrombin time (PT) during the first 6 month of life (Kuhle et al, 2003) .
Anticoagulant levels such as antithrombin, heparin cofactor II, protein C and protein S are also reduced in neonates to approximately 30-60% of that of adults (Andrew et al, 1987; Toulon, 2016) . In contrary, a 2 -macroglobulin, which inhibits fibrinolysis, is increased at birth and reaches twice the adult values by 6 months of age and remain increased throughout childhood (Andrew, 1995) . Plasma levels of coagulation parameters normalise to adult values between 1 month and 16 years, depending on the parameter (Toulon, 2016) .
Primary haemostasis has been studied less intensively, but platelet counts were shown to be normal or elevated at birth and reach adult values within 1 year after transient increases (Strauss et al, 2011; Toulon, 2016) . Although platelets are hyporeactive in the neonatal period, the bleeding time and the platelet closure time were found to be shortened in newborns and normalise during the first month of life (Roschitz et al, 2001; Sola-Visner, 2012; Toulon, 2016) .
In summary, the paediatric haemostatic system is evolving during childhood but is yet functional, as infants and children rarely suffer from haemorrhagic or thromboembolic complications spontaneously or in presence of minor challenges (Kuhle et al, 2003) . Given that thrombosis risk for comparable risk factors is substantially reduced in children as compared to adults, developmental haemostasis may even provide a protective mechanism and hence contribute to the decreased risk of thromboembolic events in children (Ignjatovic et al, 2011; Kenet et al, 2017) . For instance, thrombosis in children with nephrotic syndrome occurs in only 2% of children compared with 20% of adults. Age-related differences in the coagulation system are likely candidates for this protection (Ignjatovic et al, 2011) .
Risk factors for paediatric VTE
In contrast to adults with 30-50% idiopathic VTE events, the majority of VTE diagnosed in children are considered to be provoked by risk factors and arise proximal to hospitalisation (van Ommen et al, 2001; Mahajerin & Croteau, 2017; van Ommen & Nowak-G€ ottl, 2017) . According to the multifactorial pathogenesis of VTE, most children (~90%) exhibit two or more risk factors for thrombosis at time of the event (Andrew et al, 1994) .
Risk factors for VTE in children include a variety of acquired and inherited factors, either related to certain diseases and their corresponding treatments or individual risk factors, such as environmental and genetic factors (Fig 1) .
Acquired risk factors
Risk factors related to disease include cancer diagnosis, trauma (particularly major trauma, such as lower limb or pelvic fracture), prematurity, severe infection, inflammatory diseases, poor perfusion, dehydration and reduced mobility. Preterm birth has been described recently as important risk factor for VTE not only in early childhood but also in young adulthood, even among those born late preterm (Z€ oller et al, 2014) . Infection is often cited as a risk factor in studies without precise description of location, extent, severity or inciting organism. Sometimes infection is dichotomised as focal or systemic, with systemic infection usually conferring higher risk for VTE than focal infection (Chalmers, 2006; Young et al, 2008; Meier et al, 2015; Mahajerin & Croteau, 2017) .
The most important treatment-related risk factor is the presence of a CVC, particularly in infants and neonates. More than 90% of VTE in neonates and about 50% of VTE in older children are CVC-related (van Ommen et al, 2001; van Ommen & Nowak-G€ ottl, 2017) . The frequent use of upper venous system CVCs in children also leads to a higher portion of VTEs not located in the legs when compared with adults. Further treatment-related risk factors in children are surgery, admission to ICU, length of stay in hospital (LOS), parenteral nutrition, intubation, mechanical ventilation, chemotherapy (e.g. with asparaginase or steroids), transfusion of blood products, orthopaedic procedures, inotropic support and oestrogen-containing hormonal therapy, like oral contraception (Meier et al, 2015; Biss, 2016; Landisch et al, 2017) . Oestrogen increases thrombotic risk via increase of pro-thrombotic proteins, decrease of antithrombotic factors like protein S and antithrombin and via induction of protein C resistance (Tchaikovski & Rosing, 2010; Mahajerin & Croteau, 2017) . Surgery is difficult to consistently define as a risk factor for VTE and refers to various procedures of different severity and duration. In many studies, surgery is divided into major and minor surgery, but again, these procedures are not uniformly defined (Mahajerin & Croteau, 2017) . LOS may be considered either as continuous or binary predictor variable, divided by a cut-off number of days (Mahajerin & Croteau, 2017) . Some of these factors, such as LOS, severity of injury, mechanical ventilation and ICU admission may confer risk of VTE via their contribution to reduced mobility of the patient (Meier et al, 2015) .
Individual risk factors include age, as thrombotic risk is highest in neonates and adolescents. As in adults, smoking in adolescents may play a role as mild provoking risk factor at thrombotic onset (Holst et al, 2010) . Obesity increases VTE risk through a chronic low-grade inflammatory state, platelet activation and endothelial dysfunction, but is much less studied in children than in adults (Stokes et al, 2014; Mahajerin & Croteau, 2017) . Pregnancy, postpartum period and thrombophilic abnormalities are further risk factors.
Acquired thrombophilic abnormalities include antithrombin deficiency due to asparaginase therapy, protein-losing enteropathy, nephrotic syndrome, liver disease or disseminated intravascular coagulation as well as protein S deficiency due to varicella-zoster virus infection and the presence of antiphospholipid antibodies (Biss, 2016) . Autoantibodies against the procoagulant prothrombin have also been associated with increased risk for paediatric venous thrombosis, possibly by increasing its cleavage to thrombin (Rask et al, 2010) .
Inherited thrombophilia
Inherited thrombophilias (IT) are caused by genetic variants and manifest in familial aggregation of VTE and increased recurrence of unprovoked VTE. Many previous reports rely on rare variants (<1% allele frequency) derived from small family studies, which cause a highly penetrant phenotype by impairing or deleting the function of the coded protein. Prominent examples showing up to 10-fold increased VTE risk for heterozygous carriers comprise mutations in protein C and its cofactor protein S as well as mutations in the thrombin inhibitor antithrombin, which all belong to the anticoagulation pathway (Preuss & Stoll, 2011; Kenet & Nowak-Gottl, 2012; Nowak-Gottl et al, 2013; Kenet et al, 2017) . These thrombophilias have been detected in 6Á6% (antithrombin deficiency), 7Á4% (protein C-deficiency) and 8Á2% (protein S-deficiency) of children with symptomatic thromboembolism collected in Israeli-German cohort studies. VTE recurrence rates have been reported as 38% in children with antithrombin deficiency, 24% for protein C-deficiency and 6Á6% for protein S-deficiency (Limperger et al, 2014a,b; Klostermeier et al, 2015; Kenet et al, 2017) .
A common variant in Europeans is the F5 gene mutation known as factor V Leiden (F5 R506Q, 2-7% allele frequency (Rees et al, 1995) ), which increases the clotting probability in children and adults by extending the activity of factor V (Bertina et al, 1994 G20210A is also common in Europeans showing allele frequencies of about 2-3% (Rosendaal et al, 1998) . This polymorphism is located in the 3 0 untranslated region of F2 and affects thrombosis risk in children and adults by increasing plasma prothrombin concentrations (Poort et al, 1996) . Both mutations are mild risk factors for VTE in children (Lijfering et al, 2010) . Notably, these allele frequencies vary for different ethnic groups. Although common in Europeans, both variants are rarely observed in Africans and Asians (Rees et al, 1995; Kenet et al, 2010) . Further associated susceptibility loci for paediatric VTE include genetic variants within the fibrinogen gamma and alpha chains (FGG, FGA), which were identified by a familybased association study in 244 families with affected children (Nowak-Gottl et al, 2009) . These variants influence the fibrinogen composition in the plasma independently of absolute plasma fibrinogen levels and affect the degree of cross-linking and elasticity of coagulated blood clots (Nowak-Gottl et al, 2009) . A mutation in the methylenetetrahydrofolate reductase gene (MTHFR C677T) has been described as a prothrombotic factor in first arterial ischemic stroke (AIS) and venous thrombosis in children. Mutations in this gene increase homocysteine levels in the blood stream and exhibit modest effect on thrombotic risk Heller et al, 2000; Den Heijer et al, 2005; Haywood et al, 2005) . However, this effect is controversial and remains a matter of debate (Bezemer et al, 2007; Naess et al, 2008) . Elevated lipoprotein(a) levels have been associated with paediatric VTE and AIS and may contribute to disease risk via inhibition of plasminogen activation (Nowak-G€ ottl et al, 1999; Kenet et al, 2010; Nowak-Gottl et al, 2013) , albeit the detailed link between genetic variants and lipoprotein(a) plasma levels in paediatric VTE patients need further investigation.
However, all these gene variants cannot fully explain the observed heritability in paediatric VTE. This may be partly due to further relevant variants with small effect sizes, which have not yet been identified. Variants residing in genes less obviously connected to coagulation pathways require hypothesis-free genome-wide approaches to be discovered. Recently, the first genome-wide association study (GWAS) in paediatric VTE has been reported utilizing 212 affected offspring trios and complemented by next generation sequencing (R€ uhle et al, 2016) . It revealed a new susceptibility region on chromosome 6 comprising the genes small ArfGAP 1 (SMAP1), beta-1,3-glucuronyltransferase 2 (B3GAT2) and regulating synaptic membrane exocytosis 1 (RIMS1) (R€ uhle et al, 2016) . These genes are involved in vesicle processing in blood cells, but need further functional studies to investigate the underlying biological mechanisms in VTE. Additionally, this study indicated the ABO locus, which determines the blood group and is a well-established VTE risk factor in adults (Tr egou€ et et al, 2009) , to be also associated with paediatric VTE, albeit shortly missing genome-wide significance (R€ uhle et al, 2016) . Kerlin et al (2015) reported a feasibility study for developing a paediatric-specific clinical probability tool for VTE using retrospective data obtained from a major tertiary care children's hospital. The study sample comprised a training dataset of 389 probands consisting of 91 cases and 298 controls with similar demographic characteristics except for gender, with VTE being more common in male than in female children (68Á1% vs. 41Á9%). VTE risk was analysed for 32 potential predictor variables selected from adult-and paediatric specific VTE parameters. From these, seven predictor variables were significantly associated by univariate analysis including male gender, utilization of a central venous access device (CVAD), loss of CVAD patency, active cancer, pitting oedema and dusky discoloration of the extremity. Documentation of an alternative diagnosis by the clinician was the only variable predictive of negative VTE imaging. The model building was simplified by merging similar variables, such as oedema and/or discoloration (merged to "asymmetric extremity") and CVAD utilization and/or dysfunction (merged to "CVAD").
Risk prediction modelling of VTE in paediatric patients
These predictor variables were used for building the final risk prediction model using multivariable logistic regression modelling in 326 probands. Sixty-three probands of the initial training set had to be removed due to incomplete data. Male gender {odds ratio [OR] [95% confidence interval (CI)] = 2Á96 [1Á68-5Á22], P < 0Á001}, CVAD [OR (95% CI) = 1Á90 (1Á07-3Á39), P = 0Á029] and alternative diagnosis [OR (95% CI) = 0Á33 (0Á16-0Á66), P = 0Á002] were still significantly associated in the multivariate model, while asymmetric extremity [OR (95% CI) = 1Á81 (0Á99-3Á31), P = 0Á052] and active cancer [OR (95% CI) = 1Á73 (0Á79-3Á78), P = 0Á169] were not. This model was tested in an additional validation cohort comprising 149 probands (41 cases, 108 controls) showing an [AUC (95% CI) of 0Á64 (0Á54-0Á73), P = 0Á011]. The authors concluded that clinical probability tools for paediatric VTE are feasible and could be applied to improve the timely detection of childhood VTE. They recommend developing separate models for different patient subgroups like idiopathic, catheter-related or cancer-related VTE patients (Kerlin et al, 2015) . An overview of risk models presented in this review is given in Table II .
VTE in hospitalised patients
Atchison et al (2014) developed a risk model and an associated risk score for hospital-associated (HA) VTE specific to non-critically ill children. Fifty patients hospitalised for more than 24 h, who developed VTE in hospital were matched with 350 randomly selected, contemporaneous control patients not showing VTE. Starting with 15 putative clinical risk factors, univariate logistic regression analysis identified Table II . Risk assessment models in paediatric venous thromboembolism. presence of a CVC, LOS > 4 days and infection as the most strongly associated risk factors for HA-VTE. The two latter factors are concordant with the findings of Branchford et al (2012) in an independent hospitalised paediatric population. The three risk factors were combined in a multivariate regression model weighted for the corresponding ORs, ranging from 5Á3 to 27Á7, to create a point-scaled HA-VTE risk score. This point scale ranges from one point (only the least stringent risk factor present, i.e. LOS > 4 days) to eight points (all risk factors present) and correspond to estimated risks ranging from 0Á1% to 12Á5%, respectively. If no contraindications apply, the authors recommend chemical thromboprophylaxis for a score of eight points, mechanical prophylaxis by pneumatic compression devices for a score of seven points and observation without specific prophylactic intervention for a score of six points or less (Atchison et al, 2014) . This risk score still needs prospective evaluation in larger cooperative studies but may lead to a pragmatic approach for electronic health record-based screening and risk-stratified preventive measures for HA-VTE in non-critically ill hospitalised children, who comprise the majority of paediatric inpatients at most medical centres. Given that HA-VTE risk factors were found to differ between critically ill and non-critically ill children, the same group developed another risk score for HA-VTE in criticallyill children not undergoing cardiothoracic surgery (Arlikar et al, 2015) . A total of 57 paediatric patients with almost any acute illness as a primary diagnosis assigned to critical care units except for major burns were included in the study. These children stayed in hospital for at least 24 h and developed VTE in hospital. Additionally, 171 randomly selected critically ill children without HA-VTE served as controls. As for non-critically ill children, Arlikar et al (2015) started their analysis with a univariate logistic regression of 18 putative risk factors and found gender, mechanical ventilation, presence of a CVC, significant infection, malignancy, chronic inflammatory disease, LOS > 4 days, cardiac catheterization and history of VTE to be significantly associated. In the multivariate logistic regression model, only CVC [OR (95% CI) = 26Á64 (7Á46-95Á13), P < 0Á001], LOS > 4 days [OR (95% CI) = 20Á22 (2Á27-180Á07), P = 0Á007] and significant infection [OR (95% CI) = 3Á41 (1Á13-10Á29), P = 0Á029] remained as independent, statistically significant risk factors for HA-VTE. These risk factors were used for building a point-scaled risk score weighted for the corresponding ORs, assigning eight points for CVC, six points for LOS > 4 days and one point for significant infection. The estimated risks for HA-VTE among children with scores of 15 points, 7-14 points, and 0-6 points were 8Á8%, 1Á3% and 0Á03%, respectively (Arlikar et al, 2015) . Again, this risk score requires validation in further prospective studies. In case of positive validation, the authors recommend pharmacological thromboprophylaxis (low-dose anticoagulation, if no elevated bleeding risk indicated) for a score of 15 points, mechanical prophylaxis for scores of 7-14 points and observation without specific prophylactic intervention for lower scores. It is notable that the two scores for critically-ill children and non-critically ill paediatric patients are comprised from the same risk factors and only differ by the weighting of the risk factor components (Atchison et al, 2014; Arlikar et al, 2015) .
Another model is proposed by Sharathkumar et al (2012) , who developed a Peds-Clot clinical decision rule (PCDR) for identifying hospitalised children with a predisposition for VTE. The authors recruited 173 children with diagnosed VTE and 346 controls that matched patient's characteristics as the derivation cohort. In a first univariate analysis they tested 20 putative risk factors for association with VTE using Fisher exact tests for categorical variables and t-test for continuous variables. They identified LOS > 7 days, presence of central venous catheter, ICU admission, infection, prolonged immobilisation, use of birth control pills, body mass index, mechanical ventilation and perinatal trauma to be significantly associated with VTE. From these, the six predictor variables LOS > 7 days [OR (95% CI) = 9Á55 (4Á57-19Á96),
and use of birth control pills [OR (95% CI) = 9Á04 (2Á62-31Á21), P = 0Á0005] were selected for the multivariate logistic regression model. Based on the beta-coefficients of the final logistic model, the risk score was calculated using three points for prolonged immobilisation, two points each for LOS and birth control pills, one point each for presence of a CVC and infection and 0Á5 points for ICU admission. A cut-off of three or more points was determined to identify patients at high risk. This score was applied to a validation cohort of 100 cases and 100 controls and showed an AUC (95% CI) of 0Á88 (0Á83-0Á92). Sensitivity of the model was 57% and specificity 88%. The authors recommend that thromboprophylaxis should be considered for those patients identified to be at high risk (Sharathkumar et al, 2012) . Meier et al (2015) implemented a risk assessment model especially for hospitalised adolescents. Their method is based on an intensive literature survey and focused on 44 articles selected for investigation. Patients aged 10-17 years are assigned to three risk categories of low, moderate and high risk, respectively. Risk assessment is recommended at time of admission and at 48-72 h of hospitalisation. Patients without any risk factors present are assigned to the low-risk group. Patients with no altered mobility but multiple other risk factors or patients with altered mobility and up to one further risk factor are considered at moderate risk. Finally, patients with altered mobility and multiple other risk factors belong to the high-risk category. Depending on the risk category, the recommended intervention consists of early ambulation (low-risk), mechanical thromboprophylaxis (moderate-risk) and additional pharmacological thromboprophylaxis (highrisk). These recommendations are based on the assumption that contraindications for mechanical or chemical thromboprophylaxis have been excluded (Meier et al, 2015) .
VTE in trauma patients
While VTE is a major source of morbidity in adult trauma patients, with an estimated incidence as high as 20-58% in patients without appropriate thromboprophylaxis (Geerts et al, 1994 (Geerts et al, , 2008 , incidence of VTE observed in paediatric trauma patients is considerably lower, namely less than 1% of patients (Cyr et al, 2006; Van Arendonk et al, 2013) . Several risk factors associated with VTE in paediatric trauma patients have been described in the literature, such as injury severity, age, major surgery, poor perfusion, mechanical ventilation, immobility and CVC placement (Cyr et al, 2006; Hanson et al, 2010; Van Arendonk et al, 2013) , but standardised procedures for risk estimation are still lacking. As there is no consensus for administering thromboprophylaxis in paediatric trauma patients to date, risk prediction tools may guide clinical practice of VTE management in paediatric trauma patients.
Connelly et al (2016) developed a simple clinical prediction tool for the risk of VTE in paediatric trauma patients based on clinically relevant variables available early during hospital admission. They accessed data from >500 000 paediatric patients from 856 trauma centres using the US National Trauma Data Bank (NTDB). From these, 1141 patients had diagnosed DVT, 926 pulmonary embolism (PE) and 51 both DVT and PE. A total of 24 potential risk factors, including injury severity, patient characteristics and applied treatments, were used for developing a risk prediction model based on multivariate logistic regression. Injury severity given as Glasgow Coma Scale (GCS) score, admission to ICU, age category and major surgery were identified as most strongly associated predictors for VTE within the training dataset consisting of half of the available VTE cases and controls from the original dataset. The mechanism of injury as well as the specific type of major surgery did not show any relevant impact on model performance. The final model consisted of 10 clinical predictor variables (GCS score, age, sex, intubation, admission to ICU, transfusion of blood products, CVC placement, pelvic fracture, lower extremity fracture and major surgery) and provided an excellent discrimination of VTE cases and controls in the validation data set as shown by an AUC (95% CI) of 0Á932 (0Á922-0Á943) (Connelly et al, 2016) . The results of the VTE prediction model were presented as a score using an additive point scale for the predictor variables derived from the corresponding ORs. A score of 0-523 points corresponds to low VTE risk (<1%), scores of 524-688 points correspond to medium risk (1-5%) and scores of 689-797 points correspond to high risk (>5%). As potential therapeutic strategy, the authors recommend no intervention in the low-risk group, a screening protocol and mechanical thromboprophylaxis in the intermediate-risk group and a screening protocol, mechanical and pharmacological thromboprophylaxis in the patients at high risk for VTE, provided no contraindication of bleeding tendency is present. Yen et al (2016) analysed a total of 17 366 trauma patients of 21 years or younger obtained from the Johns Hopkins Hospital trauma registry to derive their ROCKIT (Risk of Clots in Kids with Trauma) risk prediction score. VTE was diagnosed in 49 patients (0Á28%). This data was combined with data reported by Van Arendonk et al (2013) from 402 329 patients of 21 years and younger stored in the NTDB. Based on both studies, they included six risk factors into their multivariate logistic regression model, namely age, GCS, injury severity score (ISS), blood transfusion, intubation and major surgery. A weighted scoring system was designed from both studies based on the beta coefficients of the categorised risk factors obtained from logistic regression. The score ranges from 0 (low risk) to 23 points (high risk). The risk score was tested within an independent cohort of 282 535 patients aged 21 years and younger from the NTDB and performed well in discriminating VTE cases from controls, as indicated by an AUC (95% CI) of 0Á911 (0Á905-0Á917). Using a cut-off score of 17 or above, the incidence of VTE was over 2%, which is recommended as the threshold for implementation of VTE prophylaxis (Yen et al, 2016) .
Another model was developed by Landisch et al (2017) , based on previously described VTE prophylaxis guidelines (Hanson et al, 2012) . From a total of 14 VTE risk factors tested in 588 ICU patients, consisting of VTE 23 cases and 565 controls, 4 risk factors significantly associated in univariate association analysis were selected for a multivariate risk prediction model based on logistic regression. These comprise CVC usage [OR (95% CI) = 5Á2 (1Á12-24Á30), P = 0Á04], administration of inotropes [OR (95% CI) = 7Á7 (1Á92-31Á09), P < 0Á01], immobilisation [OR (95% CI) = 5Á5 (1Á56-19Á14), P = 0Á01] and GCS < 9 [OR (95% CI) = 1Á3 (1Á04-1Á5), P = 0Á02]. Age was not significantly associated in the model, but because of an abrupt transition to adult-like VTE risk for paediatric trauma patients at age 13 years, which is reported in literature (Van Arendonk et al, 2013) , the regression model has been adjusted for age (≥13 years). When applying the model in their data set, it performed well in discrimination VTE and non-VTE patients as indicated by an AUC (95% CI) of 0Á92 (0Á88-0Á96). An independent cohort for validation of the model performance was not available.
VTE in oncology patients
Venous thromboembolism is a leading cause of death in adults with cancer (Khorana et al, 2007) . Given that 7-14% of paediatric oncology patients will experience a symptomatic DVT and over 40% will experience an asymptomatic DVT as a secondary adverse outcome of cancer treatment (Bajzar et al, 2006) , it is of eminent importance for clinical management to determine sub-groups of children with increased risk for DVT. Recently, Spavor et al (2016) utilised clinical variables in 218 survivors of childhood cancer from a Canadian multicentre case control study to identify children at increased DVT risk at the time of their cancer diagnosis. From these, 63 patients suffering symptomatic DVT confirmed by objective imaging tests during their cancer treatment were considered as cases and 155 cancer survivors without DVT, but with matching demographic data, were used as controls. Clinical variables under investigation were easy to determine and included age at cancer diagnosis, type of cancer, non-O blood group and treatment with platinum agents, steroids, methotrexate, anthracyclines, asparaginase or vinca alkaloids. Association with age showed a bimodal characteristic in univariate association analysis with increased risk in younger (<2 years) and older (>10 years) children.
The authors generated a multivariate summary model for predicting DVT risk by using stepwise logistic regression (Spavor et al, 2016) . The final model consisted of categorised age at cancer diagnosis [4 age intervals with highest OR (95% CI) for children older than 10 years compared to the reference interval of 3Á8 (1Á7-8Á5), P = 0Á001], non-O blood group [OR (95% CI) = 2Á2 (1Á2-4Á4), P = 0Á016] and asparaginase treatment [OR (95% CI) = 2Á1 (1Á1-4Á0), P = 0Á027], which resulted in an AUC of the model applied in the dataset of 0Á67. The findings are similar to the results in the general paediatric population with DVT, which show increased prevalence of DVT in younger children and adolescents as well as in adult patients with non-O blood group (Andrew et al, 1994; Dentali et al, 2012) . Additionally, Mizrahi et al (2015) . also reported non-O blood group as an independent risk factor for VTE in children with acute lymphoblastic leukaemia in a retrospective study of 523 patients. The model devised by Spavor et al (2016) may help to identify paediatric oncology patients at increased risk for DVT at time of their cancer diagnosis. However, the results from this study need to be validated in an independent study cohort.
Genetic risk prediction
Genetic testing plays a minor role in risk prediction in paediatric DVT, despite the proven impact of inherited thrombophilia. Several genetic risk prediction tools have been developed for adults (De Haan et al, 2012; Soria et al, 2014; Wassel et al, 2015; Crous-Bou et al, 2016) , but corresponding models for paediatric data are missing.
In contrast to adults, most VTE events in children are associated with clinical risk factors, such as CVC placement. However, inherited thrombophilic factors may interact with these acquired risk factors and add to rare, unprovoked thrombotic events. It remains a matter of discussion whether it is useful to test inherited thrombophilia at least for the five most prominent genetic risk factors: F5 R506Q mutation, F2 G20210A mutation and deficiencies of antithrombin, protein C or protein S in children with a first venous thrombotic event (van Ommen & Nowak-G€ ottl, 2017) . To-date, the presence of an inherited thrombophilic defect does not alter the acute antithrombotic management in children (Monagle et al, 2012) .
Genetic testing of paediatric patients with VTE may be of additional benefit for the identification of asymptomatic relatives at risk for thrombophilia. These individuals could avoid thrombotic risk factors, such as smoking, obesity and oral contraceptives, and benefit from thromboprophylaxis in high-risk situations. van Ommen and Nowak-G€ ottl (2017) recommend thrombophilia testing in adolescents with unprovoked VTE and in children with a positive family history for VTE as they are at highest genetic risk for thrombotic events.
Future perspectives
The strategy of risk stratification approaches gives rise to the idea of personalised medicine. In this concept, multiple genetic and/or physiological laboratory tests are analysed in combination with clinical parameters and patient history to provide the optimal prophylaxis and treatment strategy for an individual patient. The remarkable progress in genomics in recent years, driven by microarray-based and next generation sequencing approaches, raised expectations for translating these highly complex data into clinical practice. However, to date, the genomics approach has not yet found its way to the bedside and plays only a minor role in risk assessment (Nagalla & Bray, 2016) .
Many genetic loci identified by GWAS exhibit only small effect sizes with unknown biological function, and potential gene-gene, gene-environment and pharmacogenetic interactions further multiply the complexity of the data. Current methods to implement robust personalised risk prediction based on genomic data are limited and, for the foreseeable future, personalised thrombosis management will stick to the traditional approaches grounded in thorough patient history, physical examination and plasma-based haemostasis/thrombosis laboratory testing (Nagalla & Bray, 2016) . Further research is necessary for translating complex genomic, transcriptomic and/or epigenomic data into personalised clinical practice. However, the promising progress in machine learning technology may support these efforts and may complement the widely used logistic regression models for risk prediction (Kruppa et al, 2012; Held et al, 2016) . Given an adequate set of training data, machine learning approaches can be trained to identify complex predictor patterns in highly parallel datasets and may help to exploit complex genomic data.
Conclusion
Children may benefit from robust thrombosis risk assessment models and, accordingly, personalised thrombosis management, as have been established for adults. Current guidelines for thrombosis prophylaxis in paediatric patients are based on limited evidence or have been extrapolated from adult data and do not weight the impact of different risk factors. Risk assessment is further complicated by the low incidence of paediatric VTE and the high portion of CVC-related VTE, which is hardly manageable by thromboprophylaxis.
Available studies on paediatric VTE risk prediction mostly suggest using readily accessible clinical data to stratify patients into categories of low, medium and high thrombosis risk. For low-risk patients, further observation without intervention is sufficient, as recommended by most studies. For patients at medium risk, mechanical thromboprophylaxis, such as anti-embolism stockings and intermittent pneumatic compression devices, are recommended, while chemical thromboprophylaxis, such as heparin or oral anticoagulants, are recommended for high-risk patients only, provided no contraindication is present.
Current studies frequently suffer limitations, such as small sample size, reducing the statistical power to detect relevant predictor variables. Selected predictor variables differ for reported models even for similar patient subgroups raising the question of whether some of the predictors are artefacts of the respective datasets. Predictors are mostly selected for univariate association significance and do not represent potential combined effects and risk factor interactions. Interactions of age with other risk factors may be of particular interest, because they may reflect the transformation from paediatric to adult risk models as the child grows up. A consistent definition is missing for some risk factors as well as uniform patient inclusion and exclusion criteria. For some of the models, no appropriate validation cohort was available to confirm the performance of the model. The retrospective design of many studies brings further limitations regarding the completeness and reliability of the clinical data.
To-date, most risk assessment models focus on clinical variables and whether, or to which extent, the addition of biomarkers may improve the models at reasonable costs is unclear. Testing for genetic thrombophilia is currently not part of clinical routine in paediatric VTE risk assessment, although some genetic risk factors are well established. Future studies may include genetic risk factors and will probably aid further improvement of risk prediction models, not only to prevent VTE but also improve the quality of life of children affected by severe diseases.
